Reports Q1 revenue $ $181.20M , consensus $171.55M. "Myriad Genetics had a strong start to 2023, with first quarter revenue growth of 10% year-over-year driven by solid execution and teamwork across our Oncology, Women’s Health and Mental Health businesses and our enterprise support services team," said Paul J. Diaz, president and CEO, Myriad Genetics. "We’re pleased with ongoing share gains in our hereditary cancer testing franchise, particularly the 32% year-over-year volume growth in Women’s Health, driven by competitive account wins and increased adoption by providers of MyRisk for patients whose family history puts them at a higher risk for cancer. We believe first quarter performance reflects Myriad’s stronger commercial infrastructure resulting from the improvements made over the last few years, and we are thrilled to be recognized by 86% of our employees as a Great Place To Work(R)." Mr. Diaz concluded, "We remain confident in our ability to achieve our goal of profitability by the fourth quarter and sustainable 10%+ annual organic growth as we enter 2024 based on our progress."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
- Myriad Genetics to Participate in BofA Securities Healthcare Conference
- Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
- 77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
- Myriad, Intermountain Precision now offer solid tumor testing in all states
